In a patient with cardiofaciocutaneous syndrome complicated by intractable infantile spasms (West syndrome), cardiac hypertrophy developed during adrenocorticotropic hormone treatment. Various types of antiepileptic drugs, intravenous immunoglobulin, thyrotropin releasing hormone, and a ketogenic diet were ineffective in this case. However, vigabatrin both decreased clinical seizures and improved electroencephalogram findings. Although vigabatrin has not been approved for use in Japan, the results in the present case suggest that this drug should be considered as an alternative therapy for cases of infantile spasms associated with syndromes involving cardiomyopathy or its potential risk factors, such as cardiofaciocutaneous syndrome. (J Nippon Med Sch 2016; 83: 167 171) 
Introduction
Cardiofaciocutaneous (CFC) syndrome a disorder with multiple congenital anomalies and characterized by congenital heart disease, craniofacial dysmorphia, and ectodermal abnormalities belongs to a group of syndromes caused by mutations of genes of the RAS/mitogenactivated protein kinase pathway designated as RASopathies 1, 2 . Unlike other RASopathies, CFC syndrome is complicated, in 40% to 50% of cases, by various types of seizures, with infantile spasms (West syndrome) accounting for about 10% of such cases 3, 4 .
Vigabatrin is the drug of first choice for treating infantile spasms secondary to tuberous sclerosis complex or other symptomatic or cryptogenic infantile spasms in the European Union 5 .
Here, we report on a patient with CFC syndrome, intractable infantile spasms, and hypertrophic cardiomyopathy during adrenocorticotropic hormone (ACTH) treatment in whom administration of vigabatrin decreased seizures and improved electroencephalographic (EEG) findings. We obtained consent from the patient's parents to report the clinical course.
Case Report
A girl was born to nonconsanguineous Japanese parents via cesarean section at 35 weeks' gestation because of the mother's previous history of hysteromyomectomy. There was no family history of epilepsy or neuromuscular disease, and the girl's 4-year-old sister was healthy. At birth, the patient had a body weight of 2,854 g (+0.9 SD), a height of 44.5 cm ( 0.5 SD), and a head circumference of 35.6 cm (+1.6 SD). The 1-and 5-minute Apgar scores were 4 and 6, respectively. Thus, the patient required oxygenation and was manually resuscitated with a bag valve mask. She remained in the hospital until 22 days after birth because of poor oral intake of fluids.
At the age of 4 months, infantile spasms (West syndrome) were diagnosed because of their involvement of brief symmetrical contractions of the musculature of the neck and extremities, lasting 1 to 10 minutes and occurring in clusters everyday, and hypsarrhythmia on interictal EEG (Fig. 1A) . The patient was hospitalized at 5 months of age because epileptic seizures occurred despite treatment with vitamin B6 and valproic acid.
The results of physical examination of the patient on admission were as follows: height, 58.4 cm ( 2.7 SD); To control infantile spasms, ACTH therapy was started at a dosage of 0.0125 mg/kg/day, which was ineffective and therefore increased after 2 weeks to 0.025 mg/kg/ day. However, ACTH therapy was withdrawn because cardiac ultrasonography on day 17 indicated the development of hypertrophic cardiomyopathy and a decrease of left ventricular stroke volume from 10.5 to 5.90 mL (Fig. 2) . The hypertrophic cardiomyopathy had decreased by 7 days after ACTH treatment was discontinued.
Subsequently, the patient was treated with antiepileptic (Fig. 1C) . Although the patient continued to have severe psychomotor retardation and was unable to smile or control her head, she did not require mechanical ventilation or tube feeding. After 3 months of treatment with vigabatrin, electroretinography (ERG) showed no deterioration of retinocytes compared with before treatment (Fig. 3) .
Discussion
The disorder CFC syndrome is caused by mutations of The vigabatrin-specific side effects involve bilateral peripheral visual field defects, which are estimated to occur in 30% to 50% of adults and approximately 20% in children, depending on the dosage and duration of treatment 12, 13 . Thus, it is recommended that all patient receiving vigabatrin should undergo vision testing before the start of treatment, after every 3 months of treatment, and 3 to 6 months after the end of treatment; ERG or optical coherence tomography should be considered in patients who are unable to undergo perimetry 14 . If the testing indicates peripheral visual field defects, additional confirmatory testing should be performed, and the benefits and risks of further treatment should be evaluated 14 . Although ERG is not the optimal method of vision testing, we performed ERG before and 3 months after starting vigabatrin treatment and confirmed no aggravation.
In the present case, vigabatrin was first administered 6 months after the onset of infantile spasms because it has not yet been approved for use in Japan. For patients with profound mental or motor disability, as in the present case, gazing at their parents and smiling are important aspects of their lives. We suspect that if vigabatrin had been administered earlier, the seizures would have been controlled earlier and the patient would have developed more normally. We believe that vigabatrin should be administered early to patients with infantile spasms involving profound mental retardation, and we hope that vigabatrin will be approved for use in Japan.
